Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways

BACKGROUND: Recently, progress has been made in the development of targeted therapies for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). However, drug resistance has severely limited the efficacy of anti-HER2 therapies. Pyrotinib is a novel pan-HER inhibitor. Although...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Beibei, Huang, Tingting, Jin, Yu, Yin, Han, Qiu, Hong, Yuan, Xianglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902570/
https://www.ncbi.nlm.nih.gov/pubmed/33030616
http://dx.doi.org/10.1007/s10120-020-01126-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902570/
https://www.ncbi.nlm.nih.gov/pubmed/33030616
http://dx.doi.org/10.1007/s10120-020-01126-9

Ejemplares similares